Literature DB >> 12378523

Developmental anomalies and neoplasia in animals and cells deficient in the large zinc finger protein KRC.

Carl E Allen1, Natarajan Muthusamy, Steven E Weisbrode, Joung Woo Hong, Lai-Chu Wu.   

Abstract

The large zinc finger protein KRC binds to the signal sequences of V(D)J recombination and the kappaB motif. Disruption of KRC expression in cell lines resulted in increased cell proliferation, anchorage independence of growth, and uncoupling of nuclear division and cell division. In this report, the function of KRC was studied in a RAG2-deficient blastocyst complementation animal model. KRC-deficient embryonic stem cells were generated by homologous recombination and were introduced into RAG2(-/-) blastocysts to generate KRC(-/-);RAG2(-/-) chimeric mice. The lymphoid compartments of chimeras examined at 5 weeks of age were developed, suggesting that KRC is not essential for V(D)J recombination development. However, by 6 months of age, there was a marked deficit in CD4(+)CD8(+) thymocytes in the chimeras, suggesting that KRC may be involved in T-lymphocyte survival. Additionally, one chimera developed anomalies, including postaxial polydactyly, hydronephrosis, and an extragonadal malignant teratoma. DNA analysis showed that the teratoma was derived from KRC(-/-) embryonic stem cells. The teratoma had compound tissue organization and was infiltrated with B lymphocytes. Subsequently, several immortalized KRC-deficient cell lines were established from the teratoma. In this study, growth anomalies and neoplasia were observed in animals and cells deficient in KRC, and other studies have shown allelic loss occurring at the chromosomal region of the human KRC counterpart in various tumors. We propose that KRC may be a previously unidentified tumor-suppresser gene. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378523     DOI: 10.1002/gcc.10128

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Disruption of ZAS3 in mice alters NF-kappaB and AP-1 DNA binding and T-cell development.

Authors:  Carl E Allen; John Richards; Natarajan Muthusamy; Herbert Auer; Yang Liu; Michael L Robinson; John A Barnard; Lai-Chu Wu
Journal:  Gene Expr       Date:  2007

2.  Inhibition of NF-kappaB by ZAS3, a zinc-finger protein that also binds to the kappaB motif.

Authors:  Joung-Woo Hong; Carl E Allen; Lai-Chu Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

3.  Purification, identification, and cloning of lysoplasmalogenase, the enzyme that catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogen.

Authors:  Lai-Chu Wu; Douglas R Pfeiffer; Elisabeth A Calhoon; Francesca Madiai; Guido Marcucci; Shujun Liu; Marianne S Jurkowitz
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

4.  Reciprocal regulation of nuclear factor kappa B and its inhibitor ZAS3 after peripheral nerve injury.

Authors:  Lai-Chu Wu; Virginia M Goettl; Francesca Madiai; Kevin V Hackshaw; Syed-Rehan A Hussain
Journal:  BMC Neurosci       Date:  2006-01-12       Impact factor: 3.288

5.  Regulation of T helper type 2 cell differentiation by murine Schnurri-2.

Authors:  Motoko Y Kimura; Hiroyuki Hosokawa; Masakatsu Yamashita; Akihiro Hasegawa; Chiaki Iwamura; Hiroshi Watarai; Masaru Taniguchi; Tsuyoshi Takagi; Shunsuke Ishii; Toshinori Nakayama
Journal:  J Exp Med       Date:  2005-02-07       Impact factor: 14.307

6.  Schnurri-3 (KRC) interacts with c-Jun to regulate the IL-2 gene in T cells.

Authors:  Mohamed Oukka; Marc N Wein; Laurie H Glimcher
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

Review 7.  NF-kappaB regulation: the nuclear response.

Authors:  Arun K Mankan; Matthew W Lawless; Steven G Gray; Dermot Kelleher; Ross McManus
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

8.  Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer.

Authors:  Guo-Qiang Qin; Hui-Chan He; Zhao-Dong Han; Yu-Xiang Liang; Sheng-Bang Yang; Ya-Qiang Huang; Liang Zhou; Hao Fu; Jie-Xian Li; Fu-Neng Jiang; Wei-de Zhong
Journal:  Onco Targets Ther       Date:  2014-01-24       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.